Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (481-490 of 551) with videos related to

Pageof 56
Sort By:
Plos One|May 1, 2009
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners studyJairam R Lingappa, Erin Kahle, Nelly Mugo, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Journal of Clinical Microbiology|July 21, 2021
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization AssaysAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Vaccine|March 22, 2026
DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant proteinStephen C De Rosa, Ronnie M Gravett, William O Hahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Pageof 56

Showing results (481-490 of 551) with videos related to

Sort By:
Pageof 56
Plos One|May 1, 2009
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners studyJairam R Lingappa, Erin Kahle, Nelly Mugo, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Journal of Clinical Microbiology|July 21, 2021
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization AssaysAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Vaccine|March 22, 2026
DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant proteinStephen C De Rosa, Ronnie M Gravett, William O Hahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Pageof 56